MannKind Co. Logo
US56400P7069
A2DMZL
MNKD

MannKind Co.

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 9,99 € (+169,27 %). Medianen er 9,08 € (+144,74 %).

Køb
  11
Behold
  3
Sælg
  7

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • MannKind achieves positive phase‑1b results for inhaled nintedanib in IPF

    MannKind reports positive topline results from the randomized, double‑blind phase‑1b study INFLO‑1 of inhaled nintedanib as a dry powder in patients with idiopathic pulmonary fibrosis (IPF). The 27‑patient study showed no serious adverse events, no drug‑related gastrointestinal side effects, no bronchospasms and no discontinuations or dose reductions; cough was mostly mild and transient. Overall, IPF patients received about 450 inhalations; combined with phase‑1a, 48 people were treated, 18 of them with IPF. The global phase‑2 study INFLO‑2 to further evaluate nintedanib DPI is currently recruiting and is expected to enroll around 210 participants. » Mere på de.investing.com


  • Wells Fargo upgrades MannKind after pediatric Afrezza approval, calls commercial potential a “show‑me story”

    Wells Fargo raised its price target on MannKind to $11 and kept an Overweight rating, citing FDA approval of Afrezza for patients aged 6 and older and supportive INHALE‑1 data. The approval expands Afrezza’s market to pediatric patients and caregivers. MannKind also highlighted potential near‑term upside from up to $35 million in development milestones, a 10% royalty on net sales and its role as sole manufacturer of Tyvaso DPI. » Mere på finance.yahoo.com


  • MannKind completes patient recruitment for INFLO‑1 and starts global phase‑2 for Nintedanib DPI

    MannKind has completed randomization of patients in the phase‑1b trial INFLO‑1 and has enrolled the first patient in the global phase‑2 trial INFLO‑2 for Nintedanib DPI. INFLO‑1 evaluates safety, tolerability and pharmacokinetics; results are expected in Q3 2026. INFLO‑2 aims to recruit about 210 participants at roughly 85 sites in a randomized, double‑blind 1:1:1 design over 12 weeks (with a 24‑week open extension) for dose finding and safety assessment. » Mere på de.investing.com


  • MannKind: shareholders re-elect nine directors, approve compensation and auditor

    At the annual general meeting, shareholders re-elected all nine nominated MannKind directors and voted in an advisory capacity to approve the board’s compensation. Deloitte & Touche was confirmed as the independent auditor for the fiscal year ending December 31, 2026. In quarterly results, MannKind reported a 15% revenue rise to $90 million, mainly driven by FUROSCIX following the acquisition of scPharmaceuticals, but missed the EPS forecast of -$0.01 with a non-GAAP net loss of $0.02 per share. » Mere på de.investing.com


  • MannKind records Q1 revenue up 15% and sees three near-term regulatory catalysts

    MannKind reported Q1 2026 revenue of $90 million (up 15% year-over-year), driven by the integration of FUROSCIX; the adjusted non-GAAP result showed a loss of $6.9 million. Management emphasizes strategic diversification away from a one-product model and identifies three imminent value drivers: Afrezza Pediatrics (PDUFA May 29), the FUROSCIX ReadyFlow autoinjector (PDUFA July 26), and nintedanib DPI with topline data in Q3 and the start of Phase 2 recruitment. The partnership with United Therapeutics for Ralinepag DPI was also expanded, including an upfront payment and milestones, and the revenue outlook for FUROSCIX in 2026 remains $110–120 million. » Mere på de.investing.com

I 2022 har MannKind Co. allerede udloddet 7,52 € i udbytte. Den seneste udlodning fandt sted i september 2022.

Virksomhedstal

I det seneste kvartal havde MannKind Co. en omsætning på 89,94 mio. € og et nettoresultat på -20,5 mio. €
(EUR) september 2026
YoY
Omsætning 89,94 mio. 28,51 %
Bruttofortjeneste 69,18 mio. 31,09 %
Nettoresultat -20,5 mio. 401,33 %
EBITDA -4,73 mio. 131,10 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
1,2 mia. €
Antal aktier
321,64 mio.
Højeste/laveste i 52 uger
5,91 € - 2,02 €
Udbytte Nej
Beta
1,09
P/E (PE Ratio)
-17,52
PEG (PEG Ratio)
0,17
K/I (PB Ratio)
-35,44
P/S (PS Ratio)
3,21

Virksomhedsprofil

MannKind Corporation er et biofarmaceutisk selskab, der fokuserer på udvikling og kommercialisering af inhalerede terapeutiske produkter til endokrine sygdomme og sjældne lungesygdomme (orphan lung diseases) i USA. Selskabet tilbyder Afrezza, et inhaleret insulin, der anvendes til at forbedre glykæmisk kontrol hos voksne med diabetes. Det markedsfører også Thyquidity over for voksne og pædiatriske endokrinologer samt andre sundhedsfagligt personale til behandling af hypothyreose. Selskabet har en licens- og samarbejdsaftale med United Therapeutics Corporation. Det har desuden en aftale med NRx Pharmaceuticals om at udvikle en tørpulverformulering af ZYESAMI (aviptadil), en syntetisk form af humant vasoaktivt intestinalt peptid, der skal hjælpe med at beskytte celler mod inflammatoriske tilstande. MannKind Corporation blev stiftet i 1991 og har hovedkvarter i Westlake Village, Californien.

Navn
MannKind Co.
CEO
Michael E. Castagna
Hjemsted Danbury, ca
USA
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
28.07.2004
Medarbejdere 592

Tickersymboler

Børs Symbol
NASDAQ
MNKD
Frankfurt
NNFN.F
Düsseldorf
NNFN.DU
SIX
NNFN.SW
München
NNFN.MU
🍪

Parqet  bruger cookies. Læs mere